Xeris Biopharma Holdings Return on Equity

Xeris Biopharma Holdings posts a ROE of 176.34%. That is above the Healthcare sector average of -75.84%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Healthcare stocks, a ROE near -75.84% is typical. Xeris Biopharma Holdings's 176.34% is higher that level. That is roughly 332.5% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Xeris Biopharma Holdings's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 176.34%; use YoY and peer views to separate noise from signal.

Context for 0A8E.L's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average -75.84%), and (3) consistency with growth and profitability. This page covers the first two; Xeris Biopharma Holdings's other metric pages and overview cover the third.

Judging Xeris Biopharma Holdings against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with 176.34% here, then scan peer and history charts to see if the gap is persistent.